title: [The role of atherogenic dyslipidaemia in clinical practice guidelines].
abstract: OBJECTIVE
  Atherogenic dyslipidaemia is underdiagnosed, undertreated, and under-controlled. The aim of the present study was to assess the positioning of clinical guidelines as regards atherogenic dyslipidaemia.
  
  
  METHODS
  The major clinical guidelines of scientific societies or official agencies issued between January 1, 2012 and March 31, 2015 were collected from the MEDLINE database. High-density lipoprotein (HDL) cholesterol, triglycerides, atherogenic dyslipidaemia, non-HDL cholesterol, and apolipoprotein (apo) B were gathered from the 10 selected guidelines, and it was assessed whether these parameters were considered a cardiovascular risk factor, a therapeutic target, or proposed a pharmacological strategy.
  
  
  RESULTS
  American guidelines, except the National Lipid Association (NLA), do not consider HDL cholesterol and triglycerides in cardiovascular prevention. The NLA emphasises the relevance of atherogenic dyslipidaemia. The Canadian guidelines introduced non-HDL cholesterol and ApoB as alternative targets, and proposes non-statin treatment in the presence of low HDL cholesterol and hypertriglyceridaemia. The International Atherosclerosis Society (IAS) and National Institute for Health and Care Excellence (NICE) guidelines promote the importance of non-HDL cholesterol. European, Brazilian and Japanese guidelines highlight HDL cholesterol and triglycerides, but with the limitation that the main evidence comes from sub-analysis of clinical studies.
  
  
  CONCLUSIONS
  The clinical guidelines analysed do not consider, or unconvincingly address, the importance of atherogenic dyslipidaemia.
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: 86620@parcdesalutmar.cat.
authors.forename: Juan
authors.initials: J
authors.lastname: Pedro-Botet
authors.affiliation: Centro de Salud Prosperidad, Madrid, España.
authors.forename: Teresa
authors.initials: T
authors.lastname: Mantilla-Morató
authors.affiliation: Centro de Salud de Bembibre, Bembibre, León, España.
authors.forename: Ángel
authors.initials: Á
authors.lastname: Díaz-Rodríguez
authors.affiliation: Servicio de Medicina Interna, Hospital San Pedro, Logroño, La Rioja, España.
authors.forename: Ángel
authors.initials: Á
authors.lastname: Brea-Hernando
authors.affiliation: Departamento de Medicina, Universidad de Málaga, Málaga, España.
authors.forename: Pedro
authors.initials: P
authors.lastname: González-Santos
authors.affiliation: Servicio de Endocrinología, Hospital Universitario Dr. Peset, Universitat de València, Valencia, España.
authors.forename: Antonio
authors.initials: A
authors.lastname: Hernández-Mijares
authors.affiliation: Unidad de Lípidos, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, Universitat de Barcelona, CIBERobn-ISCIII, Hospitalet de Llobregat, Barcelona, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pintó
authors.affiliation: Servicio de Medicina Interna, Hospital Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, España.
authors.forename: Jesús
authors.initials: J
authors.lastname: Millán Núñez-Cortés
mesh_terms: D050197:Atherosclerosis / Q000175:diagnosis / Q000628:therapy*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D050171:Dyslipidemias / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D017410:Practice Guidelines as Topic; D012307:Risk Factors
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids
keywords: Atherogenic dyslipidaemia; Cardiovascular prevention; Cholesterol; Colesterol; Dislipemia aterogénica; Guías de práctica clínica; Lipids; Lípidos; Practice guidelines; Prevención cardiovascular; Triglicéridos; Triglycerides